It provides a comprehensive overview of the role of SLC7A11 in fibrotic diseases affecting various organs or tissues, including the liver, lung, kidney, heart, pancreas, intestine, keloid, and cornea, describes how SLC7A11 exerts ferroptosis- and non-ferroptosis-dependent effects on fibrosis, and proposes potential therapeutic strategies for fibrotic diseases based on the distinctive characteristics of SLC7A11. This evidence concerns the gene SLC7A11 and keloid.